AU8162491A – Oxorapamycin
– Google Patents
AU8162491A – Oxorapamycin
– Google Patents
Oxorapamycin
Info
Publication number
AU8162491A
AU8162491A
AU81624/91A
AU8162491A
AU8162491A
AU 8162491 A
AU8162491 A
AU 8162491A
AU 81624/91 A
AU81624/91 A
AU 81624/91A
AU 8162491 A
AU8162491 A
AU 8162491A
AU 8162491 A
AU8162491 A
AU 8162491A
Authority
AU
Australia
Prior art keywords
oxorapamycin
Prior art date
1990-08-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU81624/91A
Other versions
AU639126B2
(en
Inventor
Gregory Francis Von Burg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1990-08-09
Filing date
1991-08-05
Publication date
1992-02-13
1991-08-05
Application filed by American Home Products Corp
filed
Critical
American Home Products Corp
1992-02-13
Publication of AU8162491A
publication
Critical
patent/AU8162491A/en
1993-07-15
Application granted
granted
Critical
1993-07-15
Publication of AU639126B2
publication
Critical
patent/AU639126B2/en
2011-08-05
Anticipated expiration
legal-status
Critical
Status
Ceased
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
C07D498/18—Bridged systems
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/04—Antibacterial agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/10—Antimycotics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P37/00—Drugs for immunological or allergic disorders
A61P37/02—Immunomodulators
A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
AU81624/91A
1990-08-09
1991-08-05
Oxorapamycin
Ceased
AU639126B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
US07/564,910
US5023263A
(en)
1990-08-09
1990-08-09
42-oxorapamycin
US564910
1990-08-09
Publications (2)
Publication Number
Publication Date
AU8162491A
true
AU8162491A
(en)
1992-02-13
AU639126B2
AU639126B2
(en)
1993-07-15
Family
ID=24256400
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU81624/91A
Ceased
AU639126B2
(en)
1990-08-09
1991-08-05
Oxorapamycin
Country Status (11)
Country
Link
US
(1)
US5023263A
(en)
EP
(1)
EP0470804A1
(en)
JP
(1)
JPH04230687A
(en)
KR
(1)
KR920004396A
(en)
AU
(1)
AU639126B2
(en)
CA
(1)
CA2048540A1
(en)
GB
(1)
GB2246776B
(en)
HU
(1)
HUT61557A
(en)
IE
(1)
IE912813A1
(en)
PT
(1)
PT98617A
(en)
ZA
(1)
ZA916155B
(en)
Families Citing this family (95)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
IL101353A0
(en)
*
1991-04-03
1992-11-15
American Home Prod
Pharmaceutical compositions for treating diabetes
US5093338A
(en)
*
1991-04-23
1992-03-03
Merck & Co., Inc.
Lipophilic macrolide useful as an immunosuppressant
US5776943A
(en)
*
1991-05-14
1998-07-07
American Home Products Corporation
Rapamycin metabolites
US5286730A
(en)
*
1991-09-17
1994-02-15
American Home Products Corporation
Method of treating immunoinflammatory disease
US5286731A
(en)
*
1991-09-17
1994-02-15
American Home Products Corporation
Method of treating immunoinflammatory bowel disease
US5164399A
(en)
*
1991-11-18
1992-11-17
American Home Products Corporation
Rapamycin pyrazoles
ZA935110B
(en)
*
1992-07-17
1994-02-04
Smithkline Beecham Corp
Rapamycin derivatives
ZA935111B
(en)
*
1992-07-17
1994-02-04
Smithkline Beecham Corp
Rapamycin derivatives
ZA935112B
(en)
*
1992-07-17
1994-02-08
Smithkline Beecham Corp
Rapamycin derivatives
US5480988A
(en)
*
1992-10-13
1996-01-02
American Home Products Corporation
Carbamates of rapamycin
US5480989A
(en)
*
1992-10-13
1996-01-02
American Home Products Corporation
Carbamates of rapamycin
US5489680A
(en)
*
1992-10-13
1996-02-06
American Home Products Corporation
Carbamates of rapamycin
US5434260A
(en)
*
1992-10-13
1995-07-18
American Home Products Corporation
Carbamates of rapamycin
USRE37421E1
(en)
1993-07-16
2001-10-23
Smithkline Beecham Corporation
Rapamycin derivatives
US5373014A
(en)
*
1993-10-08
1994-12-13
American Home Products Corporation
Rapamycin oximes
US5378836A
(en)
*
1993-10-08
1995-01-03
American Home Products Corporation
Rapamycin oximes and hydrazones
US5391730A
(en)
*
1993-10-08
1995-02-21
American Home Products Corporation
Phosphorylcarbamates of rapamycin and oxime derivatives thereof
EP0729471A1
(en)
*
1993-11-19
1996-09-04
Abbott Laboratories
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A
(en)
*
1993-11-19
1996-06-18
Abbott Laboratories
Macrolide immunomodulators
US5385910A
(en)
*
1993-11-22
1995-01-31
American Home Products Corporation
Gem-distributed esters of rapamycin
US5385908A
(en)
*
1993-11-22
1995-01-31
American Home Products Corporation
Hindered esters of rapamycin
US5385909A
(en)
*
1993-11-22
1995-01-31
American Home Products Corporation
Heterocyclic esters of rapamycin
US5389639A
(en)
*
1993-12-29
1995-02-14
American Home Products Company
Amino alkanoic esters of rapamycin
US5362735A
(en)
*
1994-02-23
1994-11-08
Smithkline Beecham Corporation
Rapamycin derivatives
US5525610A
(en)
*
1994-03-31
1996-06-11
American Home Products Corporation
42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A
(en)
1994-04-18
1994-11-08
American Home Products Corporation
Rapamycin hydroxyesters
US5463048A
(en)
*
1994-06-14
1995-10-31
American Home Products Corporation
Rapamycin amidino carbamates
US5491231A
(en)
*
1994-11-28
1996-02-13
American Home Products Corporation
Hindered N-oxide esters of rapamycin
US5563145A
(en)
*
1994-12-07
1996-10-08
American Home Products Corporation
Rapamycin 42-oximes and hydroxylamines
US5780462A
(en)
1995-12-27
1998-07-14
American Home Products Corporation
Water soluble rapamycin esters
US5922730A
(en)
*
1996-09-09
1999-07-13
American Home Products Corporation
Alkylated rapamycin derivatives
IT1289815B1
(en)
*
1996-12-30
1998-10-16
Sorin Biomedica Cardio Spa
ANGIOPLASTIC STENT AND RELATED PRODUCTION PROCESS
US6015809A
(en)
*
1998-08-17
2000-01-18
American Home Products Corporation
Photocyclized rapamycin
US6331547B1
(en)
1999-08-18
2001-12-18
American Home Products Corporation
Water soluble SDZ RAD esters
FR2809216B1
(en)
*
2000-05-17
2002-09-06
Jerome Bouillet
DEVICE INDICATOR OF A FALL OF A BODY IN A PIECE OF WATER
US6511986B2
(en)
2000-08-11
2003-01-28
Wyeth
Method of treating estrogen receptor positive carcinoma
AU2001290841A1
(en)
2000-09-19
2002-04-02
American Home Products Corporation
Water soluble rapamycin esters
US6399625B1
(en)
2000-09-27
2002-06-04
Wyeth
1-oxorapamycins
US7754208B2
(en)
2001-01-17
2010-07-13
Trubion Pharmaceuticals, Inc.
Binding domain-immunoglobulin fusion proteins
CN100402031C
(en)
2002-07-30
2008-07-16
惠氏公司
Parenteral formulations containing a rapamycin hydroxyester
US7160867B2
(en)
2003-05-16
2007-01-09
Isotechnika, Inc.
Rapamycin carbohydrate derivatives
AU2005238493A1
(en)
*
2004-04-27
2005-11-10
Wyeth
Labeling of rapamycin using rapamycin-specific methylases
WO2006115509A2
(en)
2004-06-24
2006-11-02
Novartis Vaccines And Diagnostics Inc.
Small molecule immunopotentiators and assays for their detection
AU2005302004A1
(en)
2004-10-28
2006-05-11
Wyeth
Use of an mTOR inhibitor in treatment of uterine leiomyoma
GB0503936D0
(en)
2005-02-25
2005-04-06
San Raffaele Centro Fond
Method
UA97469C2
(en)
2005-07-25
2012-02-27
Емерджент Продакт Дівелопмент Сіетл, Елелсі
Humanized cd37-specific binding immunoglobulin molecule
US20080051691A1
(en)
*
2006-08-28
2008-02-28
Wyeth
Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US8425459B2
(en)
2006-11-20
2013-04-23
Lutonix, Inc.
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8414525B2
(en)
2006-11-20
2013-04-09
Lutonix, Inc.
Drug releasing coatings for medical devices
US9700704B2
(en)
2006-11-20
2017-07-11
Lutonix, Inc.
Drug releasing coatings for balloon catheters
US20080175887A1
(en)
2006-11-20
2008-07-24
Lixiao Wang
Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
US8414910B2
(en)
2006-11-20
2013-04-09
Lutonix, Inc.
Drug releasing coatings for medical devices
US8414526B2
(en)
2006-11-20
2013-04-09
Lutonix, Inc.
Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2
(en)
2006-11-20
2015-04-07
Lutonix, Inc.
Drug releasing coatings for balloon catheters
US20080276935A1
(en)
2006-11-20
2008-11-13
Lixiao Wang
Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2
(en)
2008-08-29
2013-04-30
Lutonix, Inc.
Methods and apparatuses for coating balloon catheters
US9737640B2
(en)
2006-11-20
2017-08-22
Lutonix, Inc.
Drug releasing coatings for medical devices
TW200901989A
(en)
2007-04-10
2009-01-16
Wyeth Corp
Anti-tumor activity of CCI-779 in papillary renal cell cancer
JP2008305262A
(en)
*
2007-06-08
2008-12-18
Konica Minolta Business Technologies Inc
Printer introduction method in server and thin client environment
AU2008287195A1
(en)
*
2007-07-06
2009-02-19
Emergent Product Development Seattle, Llc
Binding peptides having a C-terminally disposed specific binding domain
US20100048913A1
(en)
2008-03-14
2010-02-25
Angela Brodie
Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8685995B2
(en)
*
2008-03-21
2014-04-01
The University Of Chicago
Treatment with opioid antagonists and mTOR inhibitors
PT2132228E
(en)
2008-04-11
2011-10-11
Emergent Product Dev Seattle
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
CA2743491C
(en)
2008-11-11
2016-10-11
Zelton Dave Sharp
Inhibition of mammalian target of rapamycin
AU2010210422A1
(en)
2009-02-05
2011-08-18
Tokai Pharmaceuticals, Inc.
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
CA2777128A1
(en)
2009-10-30
2011-05-05
Ariad Pharmaceuticals, Inc.
Methods and compositions for treating cancer
US9283211B1
(en)
2009-11-11
2016-03-15
Rapamycin Holdings, Llc
Oral rapamycin preparation and use for stomatitis
US20130195919A1
(en)
2010-03-05
2013-08-01
President And Fellows Of Harvard College
Induced dendritic cell compositions and uses thereof
CA2795544A1
(en)
2010-04-27
2011-11-03
Roche Glycart Ag
Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
JP2014519813A
(en)
2011-04-25
2014-08-21
オーエスアイ・ファーマシューティカルズ，エルエルシー
Use of EMT gene signatures in cancer drug discovery, diagnosis, and treatment
EP2532740A1
(en)
2011-06-11
2012-12-12
Michael Schmück
Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy
EP2906214A1
(en)
2012-10-12
2015-08-19
The Board of Regents of The University of Texas System
Use of mtor inhibitors to treat vascular cognitive impairment
WO2014068070A1
(en)
2012-10-31
2014-05-08
INSERM (Institut National de la Santé et de la Recherche Médicale)
Methods for preventing antiphospholipid syndrome (aps)
DK2968281T3
(en)
2013-03-13
2020-11-02
Univ Texas
MTOR INHIBITORS FOR PREVENTING THE GROWTH OF THE INTESTINAL POLYPH
AU2014236135A1
(en)
2013-03-14
2015-09-10
Thomas Jefferson University
Androgen receptor down-regulating agents and uses thereof
EP3033088A4
(en)
2013-08-12
2017-03-08
Tokai Pharmaceuticals, Inc.
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US9700544B2
(en)
2013-12-31
2017-07-11
Neal K Vail
Oral rapamycin nanoparticle preparations
ES2900426T3
(en)
2013-12-31
2022-03-16
Rapamycin Holdings Llc
Oral preparations and use of rapamycin nanoparticles
US10300070B2
(en)
2014-03-27
2019-05-28
The Brigham And Women’s Hospital, Inc.
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
CA2968049A1
(en)
2014-04-16
2015-10-22
Rapamycin Holdings, Llc
Oral rapamycin preparation and use for stomatitis
WO2015187541A1
(en)
2014-06-02
2015-12-10
Children’s Medical Center Corporation
Methods and compositions for immunomodulation
JP6692798B2
(en)
2014-09-11
2020-05-13
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・カリフオルニア
mTORC1 inhibitor
WO2017029391A1
(en)
2015-08-20
2017-02-23
INSERM (Institut National de la Santé et de la Recherche Médicale)
New method for treating cancer
ES2871499T3
(en)
2017-05-15
2021-10-29
Bard Inc C R
Medical device with drug elution coating and interlayer
WO2019002168A1
(en)
2017-06-26
2019-01-03
INSERM (Institut National de la Santé et de la Recherche Médicale)
Methods and pharmaceutical compositions for the treatment of olmsted syndrome
WO2019012024A1
(en)
2017-07-13
2019-01-17
INSERM (Institut National de la Santé et de la Recherche Médicale)
Methods for increasing expansion and immunosuppressive capacity of a population of cd8+cd45rclow/- tregs
AU2019262979B2
(en)
2018-05-01
2023-07-06
Revolution Medicines, Inc.
C26-linked rapamycin analogs as mTOR inhibitors
FI3788049T3
(en)
2018-05-01
2023-05-30
Revolution Medicines Inc
C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CN113164563A
(en)
2018-07-23
2021-07-23
因柯利尔疗法公司
Method of treatment of neurological disorders
CN113164557A
(en)
2018-07-23
2021-07-23
因柯利尔疗法公司
Methods of treating neurological disorders
WO2020053125A1
(en)
2018-09-10
2020-03-19
INSERM (Institut National de la Santé et de la Recherche Médicale)
Methods for the treatment of neurofibromatosis
EP3880266A1
(en)
2018-11-14
2021-09-22
Lutonix, Inc.
Medical device with drug-eluting coating on modified device surface
EP3952937A1
(en)
2019-04-08
2022-02-16
Bard Peripheral Vascular, Inc.
Medical device with drug-eluting coating on modified device surface
JP2022526671A
(en)
2019-04-11
2022-05-25
エンクリアー セラピーズ， インク．
Methods for improving cerebrospinal fluid and devices and systems for that purpose
WO2023288046A1
(en)
2021-07-15
2023-01-19
President And Fellows Of Harvard College
Compositions and methods relating to cells with adhered particles
Family Cites Families (7)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
ZA737247B
(en)
*
1972-09-29
1975-04-30
Ayerst Mckenna & Harrison
Rapamycin and process of preparation
US3993749A
(en)
*
1974-04-12
1976-11-23
Ayerst Mckenna And Harrison Ltd.
Rapamycin and process of preparation
US4885171A
(en)
*
1978-11-03
1989-12-05
American Home Products Corporation
Use of rapamycin in treatment of certain tumors
US4316885A
(en)
*
1980-08-25
1982-02-23
Ayerst, Mckenna And Harrison, Inc.
Acyl derivatives of rapamycin
US4401653A
(en)
*
1981-03-09
1983-08-30
Ayerst, Mckenna & Harrison Inc.
Combination of rapamycin and picibanil for the treatment of tumors
US4650803A
(en)
*
1985-12-06
1987-03-17
University Of Kansas
Prodrugs of rapamycin
JP2799208B2
(en)
*
1987-12-09
1998-09-17
フアイソンズ・ピーエルシー
Macrocyclic compound
1990
1990-08-09
US
US07/564,910
patent/US5023263A/en
not_active
Expired – Lifetime
1991
1991-08-05
AU
AU81624/91A
patent/AU639126B2/en
not_active
Ceased
1991-08-05
ZA
ZA916155A
patent/ZA916155B/en
unknown
1991-08-06
GB
GB9116945A
patent/GB2246776B/en
not_active
Expired – Fee Related
1991-08-06
EP
EP19910307195
patent/EP0470804A1/en
not_active
Ceased
1991-08-06
JP
JP3196547A
patent/JPH04230687A/en
active
Pending
1991-08-07
KR
KR1019910013631A
patent/KR920004396A/en
not_active
Application Discontinuation
1991-08-07
HU
HU912635A
patent/HUT61557A/en
unknown
1991-08-07
CA
CA002048540A
patent/CA2048540A1/en
not_active
Abandoned
1991-08-08
IE
IE281391A
patent/IE912813A1/en
unknown
1991-08-08
PT
PT98617A
patent/PT98617A/en
not_active
Application Discontinuation
Also Published As
Publication number
Publication date
EP0470804A1
(en)
1992-02-12
GB2246776A
(en)
1992-02-12
KR920004396A
(en)
1992-03-27
CA2048540A1
(en)
1992-02-10
HU912635D0
(en)
1992-01-28
GB9116945D0
(en)
1991-09-18
HUT61557A
(en)
1993-01-28
AU639126B2
(en)
1993-07-15
PT98617A
(en)
1992-06-30
GB2246776B
(en)
1993-09-29
ZA916155B
(en)
1993-04-28
IE912813A1
(en)
1992-02-12
JPH04230687A
(en)
1992-08-19
US5023263A
(en)
1991-06-11
Similar Documents
Publication
Publication Date
Title
AU639126B2
(en)
1993-07-15
Oxorapamycin
AU8791591A
(en)
1992-05-28
Tnf-muteins
AU7506491A
(en)
1991-10-24
Phonosurgery devices
AU7846991A
(en)
1992-01-02
Aminobenzodiazepines
AU7867491A
(en)
1991-12-10
Compounds
AU7804691A
(en)
1991-12-05
N-pyridinesulfonyl-N-pyrimidinyl-or-triazinylureas
AU9030991A
(en)
1992-05-26
Improved capacitor-sensor
AU1556892A
(en)
1992-09-15
2-substituted-2-imidazolines
AU7956191A
(en)
1991-12-31
Transportsystem
AU8764191A
(en)
1992-04-28
Ibuprofen-antihistamine combinations
AU1080292A
(en)
1992-08-13
Ige-receptor-antibodies
AU7726391A
(en)
1991-11-28
Slitterscorer
AU8017991A
(en)
1992-01-09
Structural elements
AU6531090A
(en)
1991-10-21
Swagable fitting
AU8624791A
(en)
1992-03-30
Compounds
AU8740291A
(en)
1992-05-20
3d-spectacles
AU7566691A
(en)
1991-11-11
Compostor
AU7587991A
(en)
1991-12-10
Electrodermatome
AU8984191A
(en)
1992-06-25
Thiadiazinones
AU8516291A
(en)
1992-04-15
Instant photograph-postcard
AU7752291A
(en)
1991-11-11
Stay
AU7709991A
(en)
1991-11-21
Phenoxyphenylsulphonyl compounds
AU7922191A
(en)
1992-01-09
2-acylamino-7-chlorobenzothiazoles
AU8710691A
(en)
1992-04-28
Ibuprofen-diuretic combinations
AU1588892A
(en)
1992-11-02
Watch-strap
None